Astrazeneca Leading In Covid-19 Vaccine Race, Moderna Not Far Behind: WHO

AstraZeneca's experimental Covid-19 vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organization's (WHO) chief scientist said on Friday.

The British drugmaker has already begun large-scale, mid-stage human trials of the vaccine, which was developed by researchers at University of Oxford.

This week, signed its tenth supply-and-manufacturing deal.

"Certainly in terms of how advanced they are, the stage at which they are, they are I think probably the leading candidate," WHO chief scientist Soumya Swaminathan told a news conference.

"So it's possible they will have results quite early."

Swaminathan said Moderna's Covid-19 vaccine candidate was "not far behind" AstraZeneca's, among more than 200 candidates, 15 of which have entered clinical trials.

ALSO READ: Coronavirus LIVE: Vaccine tests need over $30 bn in 12 months, says WHO

"We do know that Moderna's vaccine is also going to go into phase three clinical trials, probably from the middle of July, and so that vaccine candidate is not far behind," she said.

"But I think certainly has a more global scope at the moment in terms of where they are doing and planning their vaccine trials."

The WHO is in talks with multiple Chinese manufacturers, including Sinovac, on potential vaccines, as well as with Indian researchers, Swaminathan said.

She called for drugmakers to consider collaborating on Covid-19 vaccine trials, similar to the WHO's ongoing Solidarity trial for drugs. A WHO-led coalition fighting the pandemic on Friday asked government and private sector donors to help raise $31.3 billion in the next 12 months to develop and deliver tests, treatments and vaccines for the disease. The initiative is called the ACT-Accelerator.

Andrew Witty, Special Envoy for the ACT-Accelerator, said it was important to consider a "portfolio of research efforts" for vaccines.

"It's still very early days in this journey, we may be super lucky - which would be terrific - and have an early win," Witty said. "Even if it takes 12 to 18 months that would be without precedent, the world's fast development of vaccine."

RECENT NEWS

Titi Coles Legacy In Finance: Pioneering Diversity And Leadership

Titi Cole, one of the most senior Black women in the world of finance, recently exited her high-profile role at Citi. He... Read more

Rising Rates, Rising Challenges: Bankers Adapt To Serve Troubled Companies In A Changing Economic Landscape

As interest rates climb, troubled companies are facing heightened financial pressures, prompting them to seek assistance... Read more

The Elusive Nature Of Fraud Detection: Exploring The Auditor's Dilemma

In the intricate world of financial reporting, auditors serve as guardians of integrity, tasked with uncovering discrepa... Read more

The Battle For Depositors: US Lenders Ramp Up Efforts Amidst Rate Uncertainty

In the competitive landscape of the US banking sector, retaining depositors is paramount for lenders seeking to maintain... Read more

Beyond Capital: Unveiling The Complexities Of Bank Failure Prediction

In the realm of banking, the ability to predict and prevent failures is paramount for financial stability and consumer c... Read more

Central Banks And The Economic Horizon: Steering Through Uncertaintie

In the evolving landscape of global financial markets, the strategic role of central banks has come under intense scruti... Read more